Findings

What do systematic reviews say?

8 questions · 8 findings · 5 reviews · Gut

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 12.5%GRADE not reported 0 · 0%Very low 5 · 62.5%Low 2 · 25%Moderate 0 · 0%High 0 · 0%

High dose PEG vs low dose PEG

Adverse events · patients aged 0 to 18 years with a diagnosis of functional constipation

It is very uncertain whether high dose PEG changes adverse events compared with low dose PEG (very low certainty).

1 finding from 1 review

Osmotic and stimulant laxatives for the management of childhood constipation 2016 · Cochrane Headline outcomes only
RR 1 [0.33, 5.88]
1 study · 90 participants
Very low

High dose 5‐ASA vs low dose 5‐ASA

Adverse events · people with surgically‐induced remission in Crohn's disease

High dose 5‐ASA showed no clear difference in adverse events compared with low dose 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.04 [0.15, 7.24]
1 study · 206 participants
Low

Rabeprazole at higher doses (1 mg/kg) vs rabeprazole at lower doses (0.5 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 127 participants
Very low

Pantoprazole in higher doses (1.2 mg/kg) vs pantoprazole at lower doses (0.3 mg/kg)

Adverse events · GORD in children over 1 year of age

1 finding from 1 review

Pharmacological treatment of gastro‐oesophageal reflux in children 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 60 participants
Very low

High dose 5‐ASA vs low dose 5‐ASA

Serious adverse events · people with surgically‐induced remission in Crohn's disease

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

High‐volume continuous veno‐venous hemofiltration (CVVH) vs standard CVVH

Adverse events · adults with severe acute pancreatitis

It is very uncertain whether high‐volume continuous veno‐venous hemofiltration (CVVH) changes adverse events compared with standard CVVH (very low certainty).

1 finding from 1 review

Continuous veno‐venous hemofiltration for severe acute pancreatitis 2019 · Cochrane Headline outcomes only
RR 1 [0.16, 6.2]
1 study · 30 participants
Very low

High dose 5‐ASA vs low dose 5‐ASA

Withdrawals due to adverse events · people with surgically‐induced remission in Crohn's disease

High dose 5‐ASA showed no clear difference in withdrawal due to adverse events compared with low dose 5‐ASA (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of surgically‐induced remission in Crohn's disease 2019 · Cochrane Headline outcomes only
RR 1.04 [0.15, 7.24]
1 study · 206 participants
Low

High‐treatment‐dose vitamin D (greater than 1000 IU/day) vs low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day)

Withdrawals due to adverse events · people with inflammatory bowel disease

It is very uncertain whether high‐treatment‐dose vitamin D (greater than 1000 IU/day) changes withdrawals due to adverse events compared with low‐treatment‐dose vitamin D (400 IU/day to 1000 IU/day) (very low certainty).

1 finding from 1 review

Vitamin D for the treatment of inflammatory bowel disease 2023 · Cochrane Headline outcomes only
RR 0.89 [0.06, 13.08]
3 studies · 104 participants
Very low